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IMPORTANCE Disease severity of childhood Charcot-Marie-Tooth disease (CMT) has not been
extensively characterized, either within or between types of CMT to date.
OBJECTIVE To assess the variability of disease severity in a large cohort of children and
adolescents with CMT.
DESIGN, SETTING, AND PARTICIPANTS A cross-sectional studywas conducted among 520
children and adolescents aged 3 to 20 years at 8 universities and hospitals involved in the
Inherited Neuropathies Consortium between August 6, 2009, and July 31, 2014, in Australia,
Italy, the United Kingdom, and the United States. Data analysis was conducted from August 1,
2014, to December 1, 2015.
MAIN OUTCOMES ANDMEASURES Scores on the Charcot-Marie-Tooth Disease Pediatric Scale
(CMTPedS), a well-validated unidimensional clinical outcomemeasure to assess disease
severity. This instrument includes 11 items assessing fine and gross motor function, sensation,
and balance to produce a total score ranging from0 (unaffected) to 44 (severely affected).
RESULTS Among the 520 participants (274males) aged 3 to 20 years, CMT type 1A (CMT1A)
was themost prevalent type (252 [48.5%]), followed by CMT2A (31 [6.0%]), CMT1B (15
[2.9%]), CMT4C (13 [2.5%]), and CMTX1 (10 [1.9%]). Disease severity ranged from 1 to 44
points on the CMTPedS (mean [SD], 21.5 [8.9]), with ankle dorsiflexion strength and
functional hand dexterity test beingmost affected. Participants with CMT1B (mean [SD]
CMTPedS score, 24.0 [7.4]), CMT2A (29.7 [7.1]), and CMT4C (29.8 [8.6]) were more severely
affected than those with CMT1A (18.9 [7.7]) and CMTX1 (males: 15.3 [7.7]; females: 13.0 [3.6])
(P < .05). Scores on the CMTPedS tended to worsen principally during childhood (ages, 3-10
years) for participants with CMT4C and CMTX1 and predominantly during adolescence for
those with CMT1B and CMT2A (ages, 11-20 years), while CMT1A worsened consistently
throughout childhood and adolescence. For individual items, participants with CMT4C
recordedmore affected functional dexterity test scores than did those with all other types of
CMT (P < .05). Participants with CMT1A and CMTX1 performed significantly better on the
9-hole peg test and balance test than did those with all other types of CMT (P < .05).
Participants with CMT2A had the weakest grip strength (P < .05), while those with CMT2A
and CMT4C exhibited the weakest ankle plantarflexion and dorsiflexion strength, as well as
the lowest long jump and 6-minute walk test distances (P < .05). Multiple regression
modeling identified increasing age (r = 0.356, β = 0.617, P < .001) height (r = 0.251,
β = 0.309, P = .002), self-reported foot pain (r = 0.162, β = .114, P = .009), and self-reported
hand weakness (r = 0.243, β = 0.203, P < .001) as independent predictors of disease severity.
CONCLUSIONS AND RELEVANCE These results highlight the phenotypic variability within CMT
genotypes andmutation-specific manifestations between types. This study has identified
distinct functional limitations and self-reported impairments to target in future therapeutic
trials.
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C haracterizing the variability of disease severity withinand between types of Charcot-Marie-Tooth disease(CMT) is important to increaseknowledgeof genotype-
phenotypeassociations and improveourunderstandingof the
prognosis of this disorder. Charcot-Marie-Toothdisease is the
most common inheritedneuropathy,withanestimatedpreva-
lence of 1 in 2500.1 Next-generation sequencing has resulted
in a rapid expansionof genediscovery inCMT,withmore than
80genes identifiedandmanymorestill tobediscovered.2Char-
cot-Marie-Toothdisease is often characterizedbydistalweak-
ness, foot deformity, sensory loss, areflexia, and difficulties
with gait2,3; however, the frequencyof thesediseasemanifes-
tations and the variability within and between types of CMT
are poorly understood. While the prevalence of each type of
CMT is becoming clearer, less is knownabout the clinical char-
acteristics of each of these genetic types in childhood.
Charcot-Marie-Tooth disease type 1A (CMT1A) is the
most common form of CMT, accounting for approximately
60% of those with a genetic diagnosis.4 Although CMT1A has
been reported to be slower in progression compared with
other forms of CMT, and most participants remain ambula-
tory through their lifetime, variability exists in the severity
and rate of progression.4 Charcot-Marie-Tooth disease types
X1 and CMT2A are generally the next most common
forms4,5; however, some geographic variability exists.
Although disease severity of some of the rarer forms of CMT
has been described, to our knowledge, no study has directly
compared CMT types in childhood.4,6-8 The development of
the Charcot-Marie-Tooth Disease Pediatric Scale (CMTPedS)
has provided the opportunity to compare types of CMT
objectively and reliably in children and young adults across
multiple centers.3 The CMTPedS was developed through the
Inherited Neuropathies Consortium, which is a member of
the National Institutes of Health Rare Disease Clinical
ResearchNetwork (http://www.rarediseasesnetwork.org/).The
InheritedNeuropathiesConsortiumwasestablishedtoconduct
international collaborative researchandnaturalhistory studies
on adults and children with CMT. The CMTPedS is a linearly
weighted and responsive clinical outcome measure to assess
disease severity, and includes measures of hand dexterity,
strength, sensation, gait, balance, power, and endurance. It
provides an overall age-adjusted disability score allowing
comparison within and between participants with different
CMTtypes. Theaimof this studywas to characterize the range
of disease severity both within and between children and
adolescentswithdifferentCMTtypes enrolled in the Inherited
Neuropathies Consortium.
Methods
A total of 520 children and adolescents aged 3 to 20yearswere
enrolled across 8 sites in the Inherited Neuropathies Consor-
tium between August 6, 2009, and July 30, 2014. The 8 sites
included Children’s Hospital at Westmead, Sydney, Australia
(n = 113); University of Iowa Health Care, Iowa City (n = 92);
Wayne State University, Detroit, Michigan (n = 85); Children’s
Hospital of Philadelphia, Pennsylvania (n = 72); Carlo Besta
Neurological Institute, Milan, Italy (n = 66); National Hospital
ofNeurology andNeurosurgery andGreatOrmondStreetHos-
pital, London, England (n = 56); Nemours Children’s Hospital,
Orlando, Florida (n = 20); and University of Rochester,
Rochester, New York (n = 16). Ethics approval was obtained at
all institutionsandwritten informedconsentwasobtainedfrom
all participants and/or their parents or guardians as required.
Demographic and Physical Characteristics
Information on demographics, clinical features, and genetic
diagnosiswas collected fromall participants.Demographic in-
formation included sex, age, height, weight, and body mass
index percentile. A diagnosis of CMTwasmade using clinical
features, nerve conduction studies, family history, and ge-
netic testing. Self-reported symptomsof footpain, leg cramps,
unsteady ankles, daily trips and falls, hand pain, hand weak-
ness, hand tremor, and sensory symptoms, including tin-
gling, numbness, or burning, were obtained from all partici-
pants. Symptoms were reported as being present or absent.
Foot deformity was assessed using the validated Foot Pos-
ture Index9 andankle flexibilitywas assessedusing thehighly
reliableweight-bearing lunge test.10 The anglewasmeasured
using a digital inclinometer.
Disease Severity
The CMTPedSwas performed on all children and adolescents
bytrainedevaluatorsateachsite.TheCMTPedSmeasureshand
dexterity (functional dexterity test and 9-hole peg test),
strength (hand grip and ankle plantarflexion and dorsiflex-
ion), sensationof the lower limbs (pinprick andvibration), gait
(difficultywith heel walking, difficultywith toewalking, and
presence of foot drop), balance (Bruininks-Oseretsky Test of
Motor Proficiency, 2nd Ed),11 and function (long jump and
6-minute walk test).3 All items were assessed and raw scores
comparedwithage- andsex-matchednormative referenceval-
ues to obtain a z score. The z scores were then converted to
CMTPedS category scores ranging from 0 (unaffected) to 4
(severely affected). A category score of 0 indicates a z score
within 1 SD from the normative reference value mean. A cat-
egory score of 1, 2, or 3 represents a z score of 1 to 2, 2 to 3, or
3 to 4 SDs below normal, respectively. A score of 4 represents
Key Points
Question How does disease severity differ within and between
types of Charcot-Marie-Tooth disease (CMT) in children and
adolescents?
Findings In this multicenter cross-sectional study of 520 children
and adolescents with CMT, measured with the well-validated CMT
Pediatric Scale, participants with CMT2A, CMT4C, and CMT1B
weremore affected than those with CMT1A and CMTX1, although a
spectrum of disease severity was identified within and between
types.
Meaning These data highlight the phenotypic variability within
CMT genotypes andmutation-specific manifestations between
CMT types.
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more than 4 SDs below normal. Participants unable to per-
form an item owing to disease severity received a score of 4.
Participants unable to perform an item for other reasons (eg,
acute injury, recent surgery, behavioral issues)werenot scored
andatotal scorewasnotcalculated.The11-itemcategoryscores
were summed toobtainadisease severity scoreoutof44,with
0 being unaffected and 44 being severely affected.
Statistical Analysis
Data analysis was conducted from August 1, 2014, to Decem-
ber 1, 2015, using SPSS, version 22.0 (IBMCorp). All datawere
assessed fornormality and the appropriateparametric ornon-
parametric testsubsequentlyused.FrequencyofCMTtypesand
self-reported symptoms were calculated as percentages. A
1-sample t test was used to compare foot alignment between
participantswithCMTandnormative referencevalues for un-
affectedchildrenandadolescents.12A2 × 17 × 5-way (sex × age
[years] × CMTtype [1A, 1B,2A,4C,X1]) analysisofvariancewas
performed to evaluate differences in CMTPedS total scores as
well as individual item z scores. Significant interactions were
examinedwithTukeyposthoctests.Abivariatecorrelationma-
trixwas conducted to determine the influence of age, height,
weight,bodymass indexpercentile, symptoms, footalignment,
andankle flexibilityonCMTPedStotal scores. Significantlycor-
related itemswere entered into a stepwisemultiple regression
model thatwas reduced to themostparsimoniousmodel tode-
termine if theCMTPedS total score couldbeexplainedby these
factors.Only1 factor fromhighlycorrelatedvariables (eg,height,
weight,bodymass indexpercentile)was includedtoavoidmul-
ticolinearity.Standardizedβweightswerecalculated.Anα level
of .05 was used for statistical significance.
Results
This study included520 children andadolescents (274males)
aged3 to20years (Table 1).AnextensivenumberofCMTtypes
were represented,with themostprevalent typesbeingCMT1A
(252 [48.5%]), CMT2A (31 [6.0%]), CMT1B (15 [2.9%]), CMT4C
(13 [2.5%]), and CMTX1 (10 [1.9]%) (eTable 1 in the Supple-
ment). There were no significant differences in age between
the participants with the 5 most common types of CMT
(P < .05). Foot alignment of participants with CMTwas more
cavovarus than in unaffected children and young adults
(P < .001); however, therewas awide range of pes planus and
pes cavus features (eFigure 1 in the Supplement). Unsteady
ankles (272 [52.3%]), daily trips and falls (220 [42.3%]), and
hand weakness (216 [41.5%]) were the most frequently re-
ported symptoms for the entire cohort;when symptomswere
divided by CMT type, the frequencies varied significantly be-
tween types (eTable 2 in the Supplement). Participants with
CMT2A reported a significantly higher frequency of un-
steadyankles (21 [67.7%]), daily trips and falls (18 [58.1%]), and
hand tremor (17 [54.8]%) than did those with CMT1A (128
[45.4%], 101 [35.8%], and 92 [32.6%], respectively) (P < .05),
while participants with CMT1B (9 [60.0%]) reported signifi-
cantly more hand weakness than did those with CMT1A (98
[34.8%]) (P < .05) (eTable 2 in the Supplement).
A total of 474 children and adolescents were able to com-
plete all 11 items of the CMTPedS to obtain a total disease se-
verity score. The mean (SD) CMTPedS total score for the en-
tire samplewas21.5 (8.9) (range, 1-44).Themostaffected items
weredorsiflexion strengthof the ankle and functional dexter-
ity test of the hand with, respectively, 408 (82.3%) and 288
(56.5%) casesmore than 3 SDs belownormal (eFigure 2 in the
Supplement). Analysis of variance indicated a significant in-
teraction between age and CMT type on the CMTPedS score
(F33,245 = 1.836, P = .005) whereby the CMTPedS score
worsened with age (F17,245 = 2.334, P = .003). Scores on the
CMTPedStendedtoworsenprincipallyduringchildhood (ages,
3-10 years) for participants with CMT4C and CMTX1 and pre-
dominantly during adolescence for those with CMT1B and
CMT2A (ages, 11-20 years), while CMT1A worsened consis-
tently throughout childhood and adolescence (Figure 1).
Type of CMT also significantly influenced the CMTPedS
score (F4,245 = 17.582, P < .001) (Figure 2). Participants with
CMT1A and CMTX1 demonstrated a significantly better
CMTPedS score than did those with CMT1B (P ≤ .02), CMT2A
(P < .001), and CMT4C (P < .001), while participants with
CMT1AhadasignificantlyworseCMTPedSscore thandid those
withCMTX1 (7malesand3 females) (P = .02).Participantswith
CMT1Bexhibited significantlybetterCMTPedSscores thandid
those with CMT2A (P = .02) and CMT4C (P = .03). There was
no significant effect for sex for any CMT type (P = .77). Males
with CMTX1 (mean [SD] CMTPedS total score, 15.3 [7.7]) were
marginally more affected than females (13.0 [3.6]); however,
this finding was not significant (P = .65).
For individual CMTPedS item z scores, therewas a signifi-
cant effect for age (P < .05), whereby increasing age pro-
duced a worse score for each item. There was also a signifi-
cant effect for sex on the 9-hole peg test (F1,258 = 10.856,
P = .001), whereby females performed slower thanmales. No
other items had a significant effect for sex (P > .05). Type of
CMT had a significant effect on all CMTPedS item z scores
(P < .05) (Figure 3). For the functional dexterity test, partici-
pants with CMT4C were significantly slower than those with
all other CMT types (P < .001). For the9-hole peg test, partici-
pants with CMT1A were significantly faster than those with
CMT1B,CMT2A, andCMT4C (P < .05),while participantswith
CMTX1were significantly faster than thosewithall other types
Table 1. Physical Characteristics of the Sample
Characteristic Mean (SD) [Range]
Age, y 10.9 (4.4) [3 to 20]
Height, m 1.44 (0.24) [0.90 to 1.98]
Weight, kg 42.2 (19.7) [11.2 to 120.6]
BMI 19.1 (4.9) [11.0 to 58.2]
BMI percentile 53.2 (32.5) [0.0 to 99.9]
Foot posture index score 1.4 (4.4) [−12 to 12]
Ankle lunge test, deg 22.3 (8.3) [0.0 to 50.0]
CMTPedS total score 21.5 (8.9) [1 to 44]
Abbreviations: BMI, bodymass index (calculated as weight in kilograms divided
by height in meters squared); CMTPedS, Charcot-Marie-Tooth Disease Pediatric
Scale.
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(P < .05). Participants with CMT2A demonstrated signifi-
cantlyweakergripstrengththandidthosewithCMT1A,CMT1B,
and CMTX1 (P < .05) and participants with CMTX1 were sig-
nificantly stronger thanthosewithallother types (P < .05).Par-
ticipants with CMT2A and CMT4C had significantly weaker
ankle plantarflexion and dorsiflexion strength than did those
withCMT1AandCMTX1 (P < .05), aswell as reduced long jump
and6-minutewalk testdistances.ParticipantswithCMT2Ahad
significantly worse scores for ankle strength, long jump, and
6-minute walk test distance than did those with CMT1B
(P < .05). Participants with CMT1A and CMTX1 had signifi-
cantly better balance than did participants with CMT1B,
CMT2A, and CMT4C (P < .05).
Significantcorrelationswith theCMTPedSscorewere iden-
tified for age, height,weight, bodymass indexpercentile, foot
pain, unsteady ankles, leg cramps, hand weakness, hand
tremor, and sensory symptoms (Table 2). Multiple regression
modeling identified increasing age (r = 0.356, β = 0.617;
P < .001) height (r = 0.251, β = 0.309; P = .002), self-
reported foot pain (r = 0.162, β = 0.114; P = .009), and self-
reported hand weakness (r = 0.243, β = 0.203; P < .001) as
independent predictors of disease severity, explaining 21%
of the variance in CMTPedS total score (r2 = 0.210).
Discussion
This sample of 520 children and young adults with CMT is the
largest reported to date and shows the phenotypic variability
withinCMTgenotypesandmutation-specificmanifestationsbe-
tween types. Disease severity,measured by thewell-validated
CMTPedS, ranged from 1 to 44 and represents almost the en-
tire spectrumof thescale. Scores for the5mostprevalentgeno-
typesdifferedsignificantly.For instance,themostcommontype,
CMT1A, demonstrated a mean (SD) CMTPedS score of 19 (8),
while participants with CMT2A exhibited a markedly higher
mean score of 30 (7) and those with CMTX1 had a lowermean
scoreof 15 (7).This studyhas identifieddistinct functional limi-
tations and self-reported impairments. For example, partici-
pants with CMT2A were significantly weaker for all strength
measures,andthosewithCMT4Cperformedsignificantlyworse
for both hand dexteritymeasures.
Compared with previous studies exploring the heteroge-
neity of CMT severity,3,13 our larger cohort described in this
study comprises more than 10 participants for most types,
which provides the opportunity to examine phenotypic dif-
ferences between genotypes. When evaluating CMTPedS
scores, childrenwithCMT1AandCMTX1were less severely af-
fected than thosewithCMT1B, CMT2A, andCMT4C. Charcot-
Marie-Tooth disease type 2A, specifically caused by MFN2
(OMIM 608507) mutations, has been reported as a more se-
vere phenotype6 than other CMT2 types; however, it was not
comparedwith CMT1, CMT4, or CMTX. Charcot-Marie-Tooth
disease type 4Cwas recently reported to have a variable phe-
notype in a study of 10 siblings7; however, its severity has not
been previously compared with other CMT types. Our find-
Figure 1. Charcot-Marie-Tooth Disease (CMT) Pediatric Scale Scores During Childhood and Adolescence
for CMT Types
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Figure 2. Charcot-Marie-Tooth Disease Pediatric Scale (CMTPedS)
Total Score Differences Between Charcot-Marie-Tooth (CMT) Types
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ings confirm this variability in CMT4C, with CMTPedS scores
ranging from 15 to 40 in participants with this type. The dis-
ease severityofCMT4C (CMTPedSmean [SD] score, 29.8 [8.6])
was similar to that of CMT2A (29.7 [7.1]) and worse than that
ofCMT1A (18.9 [7.7]), andwe identifiedhanddexterity asama-
jor limitation for children and adolescents with CMT4C. Par-
ticipantswithCMT4Calsoexhibitedsignificantly reducedsen-
sation comparedwith thosewithCMT1A (P < .001). Although
sensationwas onlymeasuredbyvibration andpinprick in the
lower limbs in this study, reduced sensation may be globally
limiting hand dexterity in these participants. Variability has
also been reportedwithin otherCMT types.4,8 For instance, in
CMT1B, differentMPZ (OMIM 159440) mutations may cause
different disease severity.8 The reason for thevariability is not
wellunderstood.Arecent studyreported thatparticipantswith
CMT had more rare variants in neuropathy-associated genes
compared with unaffected participants and hence suggested
thatmutationburden inparticipantswithneuropathymaycon-
tribute to the phenotypic variability.5 Further studies follow-
ing our cohort longitudinally will investigate if the disease
progression within different types of CMT is also variable.
In our cohort, the 7 males with CMTX1 were marginally
more affected than the 3 females with CMTX1, although this
difference was not significant. It has previously been re-
ported that males with CMTX1 demonstrate a milder pheno-
type during the first 2 decades of life, with increasing sever-
ity later in life.4,14 Our findings also suggest that theCMTPedS
scores changemore rapidly inchildhoodvsadolescence inpar-
ticipantswith CMTX1. Natural history studies into adulthood
are required to clarify the severity and progression of CMTX1
in males vs females.
Charcot-Marie-Tooth disease is classically described as
length dependent, with lower limbmanifestations preceding
involvement of the upper limbs.15 The finding of height as an
independentpredictorofdisease severity supports the length-
dependency theory. Our study indicates that ankle dorsiflex-
ion strength and functional hand dexterity are the most af-
fected itemson theCMTPedS, suggesting thatbothupper limb
and lower limb manifestations are present from an early age
across all CMT types. This finding confirms a previous report
that upper limb impairment can be identified in children as
youngas 3yearswithCMT1A.16 In addition, the significantdif-
ferences between CMT types for scores of tests of the upper
limbs indicate that some formsmayhavegreater hand impair-
ment. Specifically, children with CMT4C performed much
worse on the functional dexterity test than did those with all
other typesofCMT.ChildrenwithCMT1B,CMT2A,andCMT4C
performedworse on the 9-hole peg test comparedwith those
withCMT1A,suggestingthathandandfingerdexterityaremore
significantly affected in participants with these types.
This study isnotwithout limitations.First, the small num-
ber of participants with rarer types of CMT (eTable 1 in the
Supplement) prevented a comprehensive comparison be-
tween all types of CMT. Second, this cross-sectional analysis
provides only a single time point for the CMTPedS score,
which limits an understanding of the responsiveness of this
outcomemeasure in children and adolescents with CMT.
However, cross-sectional studiesareuseful in that theycan
give some prediction for longitudinal data when one corre-
lates types, as in this case, with age. Figure 1 shows that
CMTPedS scores seemtochangemore rapidly in childhood for
those with CMT4C and CMTX1 andmore rapidly during ado-
lescence for those with CMT1B and CMT2A, while a consis-
tentprogressionwasobserved inparticipantswithCMT1A. In-
deed, multiple regression modeling indicated that older age
as well as increasing height and self-reported foot pain and
hand weakness best predicted the CMTPedS total score. In-
terventionsaddressing footpainandhandweaknessatanearly
agemay be appropriate therapeutic targets to reduce disease
severity. Although, with only 21% of the variance in the
Figure 3. Charcot-Marie-Tooth Disease Pediatric Scale (CMTPedS) Item z Score Differences
Between Charcot-Marie-Tooth (CMT) Types
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CMTPedS total score explained by these factors, specifically
targeting the most affected CMTPedS items (eg, ankle dorsi-
flexion strength, functional hand dexterity test) may also be
appropriate to reduce levels of disability. In addition, inter-
ventions targeting hand function, specifically hand and fin-
ger dexterity, might provide further benefits to reduce dis-
ease severity. Nevertheless, before trials of treatment can be
conducted, it is important to understand the rate of disease
progression in prospective natural history studies of children
and adolescents with CMT.
Conclusions
This study provides a comprehensive phenotypic character-
ization of CMT both within and between CMT types seen in
childhood. Phenotypic variabilitywithin CMTgenotypes and
mutation-specificmanifestations between typeswere identi-
fied. ParticipantswithCMT1B,CMT2A, andCMT4Cweremore
severelyaffected thanthosewithCMT1AandCMTX1.Themost
affected aspects of disease severity were ankle dorsiflexion
strength andhanddexterity.Our studyhighlights that signifi-
cant impairment is present from the earliest stages of the dis-
ease, even in participants with themilder CMT1A and CMTX1
forms.Therefore, anydisease-modifying therapies that aim to
slow or halt progression of CMT should ideally be imple-
mented during childhood. These therapies may have limited
benefits once significant axonal degeneration has occurred
in older populations. Understanding these genotype-
phenotype correlations will assist with accurately targeting
future therapeutic trials in children and adults with CMT.
ARTICLE INFORMATION
Accepted for Publication:December 17, 2015.
Published Online: April 4, 2016.
doi:10.1001/jamaneurol.2016.0171.
Author Affiliations:University of Sydney &
Children’s Hospital at Westmead, Sydney Australia
(Cornett, Menezes, Bray, Halaki, Burns);
Department of Pediatrics, Carver College of
Medicine, University of Iowa, Iowa City (R. R. Shy);
Division of Neurology, The Children’s Hospital of
Philadelphia, Philadelphia, Pennsylvania (Yum);
Department of Neurology, Perelman School of
Medicine, University of Pennsylvania, Philadelphia
(Yum); Neuromucsular Program, The Children’s
Hospital of Philadelphia, Philadelphia, Pennsylvania
(Estilow); Istituto di Ricovero e Cura a Carattere
Scientifico Foundation, Carlo Besta Neurological
Institute, Milan, Italy (Moroni, Foscan, Pagliano,
Pareyson); Medical Research Council Centre for
Neuromuscular Diseases, University College
London Institute of Neurology, Queen Square,
London, England (Laurá, Reilly); University College
London Institute of Child Health & Great Ormond
Street Hospital, London, England (Bhandari,
Muntoni); Neuromuscular Program, Division of
Neurology, Nemours Children’s Hospital, Orlando,
Florida (Finkel); Department of Neurology,
University of Rochester, Rochester, New York
(Sowden, Eichinger, Herrmann); Department of
Neurology, Carver College of Medicine, University
of Iowa, Iowa City (M. E. Shy).
Author Contributions: Ms Cornett had full access
to all the data in the study and takes responsibility
for the integrity of the data and the accuracy of the
data analysis.
Study concept and design: R.R. Shy, Estilow, M.E.
Shy, Burns.
Acquisition, analysis, or interpretation of data:
Cornett, Menezes, Bray, Halaki, R.R. Shy, Yum,
Estilow, Moroni, Foscan, Pagliano, Pareyson, Laurá,
Bhandari, Muntoni, Reilly, Finkel, Sowden,
Eichinger, Herrmann, M.E. Shy.
Drafting of the manuscript: Cornett, R.R. Shy,
Moroni, M.E. Shy, Burns.
Critical revision of the manuscript for important
intellectual content:Menezes, Bray, Halaki, R.R. Shy,
Yum, Estilow, Foscan, Pagliano, Pareyson, Laurá,
Bhandari, Muntoni, Reilly, Finkel, Sowden,
Eichinger, Herrmann, M.E. Shy.
Statistical analysis: Cornett, Burns.
Obtained funding: R.R. Shy, Pareyson, Reilly, M.E.
Shy.
Administrative, technical, or material support:
Menezes, Yum, Estilow, Foscan, Pagliano, Finkel,
Sowden, Eichinger.
Study supervision:Menezes, Bray, R.R. Shy,
Muntoni, Herrmann, M.E. Shy.
Conflict of Interest Disclosures:None reported.
Funding/Support: This study was supported by
grant U54NS065712 from the National Institutes of
Neurological Diseases and Stroke and office of Rare
Diseases (Drs Herrmann, Pareyson, Muntoni, Burns,
Laurá, M.E. Shy, Finkel, and Yum); grant G0601943
from theMedical Research Council (Dr Reilly); the
National Institute for Health Research University
College London Hospitals Biomedical Research
Centre (Drs Reilly and Laurá); the Medical Research
Council Neuromuscular Centre, the National
Institute for Health Research Biomedical Research
Centre at Great Ormond Street Hospital for
Children National Health Service Foundation Trust,
and University College London (Dr Muntoni); the
Charcot-Marie-Tooth Association (Dr Muntoni); the
Muscular Dystrophy Association (Drs Muntoni and
Burns); the National Health andMedical Research
Council of Australia, Centre of Research Excellence
1031893 (Dr Burns); Charcot-Marie-Tooth
Association of Australia (Dr Burns); the Natural
Sciences and Engineering Research Council of
Canada (Ms Cornett); and the University of Sydney
International Scholarship (Ms Cornett).
Role of the Funder/Sponsor: The funding sources
had no role in the design and conduct of the study;
collection, management, analysis, or interpretation
of the data; preparation, review, or approval of the
manuscript; and decision to submit themanuscript
for publication.
Group Information: Themembers of the Inherited
Neuropathies Consortium are as follows: University
of Iowa Health Care, Iowa City:Michael Shy, MD.
Children’s Hospital of Philadelphia, Philadelphia,
Pennsylvania: Sabrina Yum, MD. University of
Pennsylvania, Philadelphia: Steven Scherer, MD,
PhD. University of Rochester, Rochester, New York:
David Herrmann, MBBCh.National Hospital of
Neurology and Neurosurgery, London, England:
Mary Reilly, MD, andMatilde Laura, MD. Dubowitz
Neuromuscular Centre, London, England: Francesco
Muntoni, MD. University of Miami, Coral Gables,
Florida: Stephan Züchner, MD, PhD, andMario
Saporta, MD, PhD, MBA. The Children’s Hospital at
Westmead, The University of Sydney, Sydney,
Australia: Joshua Burns, PhD. Carlo Besta
Neurological Institute, Milan, Italy:Davide Pareyson,
MD. Johns Hopkins University, Baltimore, Maryland:
Thomas Lloyd, MD, PhD. Vanderbilt University,
Nashville, Tennessee: Jun Li, MD, PhD. University of
Table 2. CorrelationMatrix of Variables AssociatedWith CMTPedS Score
Variable CMTPedS Scorea P Value
Age 0.350 <.001
Sex −0.085 .06
Height 0.251 <.001
Weight 0.232 <.001
BMI percentile −0.110 .02
Foot posture index −0.032 .49
Ankle lunge test −0.076 .11
Foot pain 0.155 .001
Leg cramps 0.163 <.001
Unsteady ankles 0.191 <.001
Daily trips and falls 0.074 .11
Hand pain 0.055 .23
Hand weakness 0.263 <.001
Hand tremor 0.197 <.001
Sensory symptoms 0.125 .006
Abbreviations: BMI, bodymass index; CMTPedS, Charcot-Marie-Tooth Disease
Pediatric Scale.
a Pearson correlation coefficients.
Research Original Investigation Phenotypic Variability of Childhood Charcot-Marie-Tooth Disease
650 JAMANeurology June 2016 Volume 73, Number 6 (Reprinted) jamaneurology.com
Downloaded From: http://jamanetwork.com/ by a University College London User  on 12/19/2016
Copyright 2016 American Medical Association. All rights reserved.
Washington, Seattle:Michael D. Weiss, MD.
Nemours Children’s Hospital, Jacksonville, Florida:
Richard S. Finkel, MD.National Institutes of Health–
Intramural Branch, Bethesda, Maryland: Kenneth
Fischbeck, MD. Stanford University, Stanford,
California: John Day, MD, PhD. Cedars-Sinai Medical
Center, Los Angeles, California: Robert BalohMD,
PhD, and Richard A. Lewis MD.Harvard University/
Massachusetts General Hospital, Boston: Vera
Fridman, MD. University of Michigan, Ann Arbor:
Sindhu Ramchandren, MD, MS. University of
Minnesota, Minneapolis:DavidWalk, MD. University
of Utah, Salt Lake City:Nicholas Johnson, MD.
University of Connecticut, Storrs: Gyula Acsadi, MD,
PhD. University of Antwerp, Antwerp, Belgium:
Jonathan Baets, MD, PhD. Data Management and
Coordinating Center; Health Informatics Institute;
University of South Florida, Tampa: Jeffery Krischer,
PhD.
Additional Contributions: Stephen Reddel, MD,
PhD, Concord Repatriation General Hospital, and
the Brain andMind Research Institute, University of
Sydney, provided input on the length-dependency
analysis. He was not compensated for his
contribution.
REFERENCES
1. Skre H. Genetic and clinical aspects of
Charcot-Marie-Tooth’s disease. Clin Genet. 1974;6
(2):98-118.
2. Rossor AM, Polke JM, Houlden H, Reilly MM.
Clinical implications of genetic advances in
Charcot-Marie-Tooth disease.Nat Rev Neurol. 2013;
9(10):562-571.
3. Burns J, Ouvrier R, Estilow T, et al. Validation of
the Charcot-Marie-Tooth disease Pediatric Scale as
an outcomemeasure of disability. Ann Neurol. 2012;
71(5):642-652.
4. Fridman V, Bundy B, Reilly MM, et al; Inherited
Neuropathies Consortium. CMT subtypes and
disease burden in patients enrolled in the Inherited
Neuropathies Consortium natural history study:
a cross-sectional analysis. J Neurol Neurosurg
Psychiatry. 2015;86(8):873-878.
5. Gonzaga-Jauregui C, Harel T, Gambin T, et al;
Baylor-Hopkins Center for Mendelian Genomics.
Exome sequence analysis suggests that genetic
burden contributes to phenotypic variability and
complex neuropathy. Cell Rep. 2015;12(7):1169-1183.
6. Feely SM, Laura M, Siskind CE, et al. MFN2
mutations cause severe phenotypes in most
patients with CMT2A.Neurology. 2011;76(20):
1690-1696.
7. Varley TL, Bourque PR, Baker SK. Phenotypic
variability of CMT4C in a French-Canadian kindred.
Muscle Nerve. 2015;52(3):444-449.
8. Sanmaneechai O, Feely S, Scherer SS, et al;
Inherited Neuropathies Consortium–Rare Disease
Clinical Research Consortium (INC-RDCRC).
Genotype-phenotype characteristics and baseline
natural history of heritable neuropathies caused by
mutations in theMPZ gene. Brain. 2015;138(Pt 11):
3180-3192.
9. Redmond AC, Crosbie J, Ouvrier RA.
Development and validation of a novel rating
system for scoring standing foot posture: the Foot
Posture Index. Clin Biomech (Bristol, Avon).
2006;21(1):89-98.
10. Bennell KL, Khan KM, Matthews BL, Singleton
C. Changes in hip and ankle range of motion and hip
muscle strength in 8-11 year old novice female ballet
dancers and controls: a 12 month follow up study.
Br J Sports Med. 2001;35(1):54-59.
11. Bruininks RH, Bruininks BD. Bruininks-Oseretsky
Test of Motor Proficiency. 2nd ed. Minneapolis, MN:
NCS Pearson; 2005.
12. Redmond AC, Crane YZ, Menz HB. Normative
values for the foot posture index. J Foot Ankle Res.
2008;1(1):6.
13. Burns J, Menezes M, Finkel RS, et al.
Transitioning outcomemeasures: relationship
between the CMTPedS and CMTNSv2 in children,
adolescents, and young adults with
Charcot-Marie-Tooth disease. J Peripher Nerv Syst.
2013;18(2):177-180.
14. Shy ME, Siskind C, Swan ER, et al. CMT1X
phenotypes represent loss of GJB1 gene function.
Neurology. 2007;68(11):849-855.
15. Lencioni T, Piscosquito G, Rabuffetti M, et al.
The influence of somatosensory andmuscular
deficits on postural stabilization: insights from an
instrumented analysis of subjects affected by
different types of Charcot-Marie-Tooth disease.
Neuromuscul Disord. 2015;25(8):640-645.
16. Burns J, Bray P, Cross LA, North KN, RyanMM,
Ouvrier RA. Hand involvement in children with
Charcot-Marie-Tooth disease type 1A.Neuromuscul
Disord. 2008;18(12):970-973.
Phenotypic Variability of Childhood Charcot-Marie-Tooth Disease Original Investigation Research
jamaneurology.com (Reprinted) JAMANeurology June 2016 Volume 73, Number 6 651
Downloaded From: http://jamanetwork.com/ by a University College London User  on 12/19/2016
